DELSTRIGO

This brand name is authorized in Austria, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Netherlands, Poland, Romania, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug DELSTRIGO contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 913P6LK81M - DORAVIRINE
 

Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1 and inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Doravirine does not inhibit the human cellular DNA polymerases α, β, and mitochondrial DNA polymerase γ.

 
Read more about Doravirine
2
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE
 

Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.

 
Read more about Tenofovir disoproxil
3
UNII 2T8Q726O95 - LAMIVUDINE
 

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.

 
Read more about Lamivudine

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 DELSTRIGO Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J05AR24 J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
CA Health Products and Food Branch 02482592
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 5520-MEE-1020
EE Ravimiamet 1782930, 1782941
FI Lääkealan turvallisuus- ja kehittämiskeskus 073928
FR Base de données publique des médicaments 64419961
GB Medicines & Healthcare Products Regulatory Agency 368778
HK Department of Health Drug Office 66557
IL מִשְׂרַד הַבְּרִיאוּת 8504
LT Valstybinė vaistų kontrolės tarnyba 1086626, 1086627
NL Z-Index G-Standaard, PRK 198684
PL Rejestru Produktów Leczniczych 100416690
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W65375001, W65375002
TR İlaç ve Tıbbi Cihaz Kurumu 8699636091524
US FDA, National Drug Code 0006-5007
ZA Health Products Regulatory Authority 53/20.2.8/0233

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.